Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
Crawford, J.J., Johnson, A.R., Misner, D.L., Belmont, L.D., Castanedo, G., Choy, R., Coraggio, M., Dong, L., Eigenbrot, C., Erickson, R., Ghilardi, N., Hau, J., Katewa, A., Kohli, P.B., Lee, W., Lubach, J.W., McKenzie, B.S., Ortwine, D.F., Schutt, L., Tay, S., Wei, B., Reif, K., Liu, L., Wong, H., Young, W.B.(2018) J Med Chem 61: 2227-2245
- PubMed: 29457982 
- DOI: 10.1021/acs.jmedchem.7b01712
- Primary Citation of Related Structures:  
5VFI - PubMed Abstract: 
Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, respectively. Preclinical studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus ...